# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target...
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Sell and raises the price target ...
Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and raises the price target fro...
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
BMO Capital analyst Kostas Biliouris downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Market Perform and lo...
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therape...
Leerink Partners analyst Mani Foroohar upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and ra...